Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

NCT00002531 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.

Conditions

Interventions

DRUG

asparaginase

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

leucovorin calcium

DRUG

mercaptopurine

DRUG

methotrexate

DRUG

mitoxantrone hydrochloride

DRUG

prednisolone

DRUG

teniposide

DRUG

thioguanine

DRUG

vincristine sulfate

DRUG

vindesine

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Principal Investigators

  • Dieter Hoelzer, MD, PhD · Johann Wolfgang Goethe University Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002531 on ClinicalTrials.gov